Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
These approvals will incite a modest reorganisation in the market of antibody-based therapies for the illness.
Comment & Opinion
Concerning safety signals and positive efficacy for AstraZeneca’s in vivo CAR-T
AD/PD 2026: Aspen’s sasineprocel reaches primary endpoint in Phase I/IIa ASPIRO trial
AD/PD 2026: Three-year data confirms slow amyloid re-accumulation following Kisunla treatment completion
AD/PD 2026: J&Js anti-tau drug posdinemab fails in early Alzheimer’s disease
Enhancing clinical trials with real-world data
AD/PD 2026: Roche’s prasinezumab shows promise on PD progression with five-year data
AD/PD 2026: IRLAB’s pirepemat shows promise in reducing falls in Parkinson’s disease
